Journals / Turkish Journal of Gastroenterology / 2001 / Cilt: 12 - Sayı: 1

Kronik karaciğer hastalığının evresi ile trombosit fonksiyonları arasındaki ilişki

Relationship between stage of chronic liver disease and thrombocyte functions

Pages
13–18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the cirrhotic stage, however, there were significant functional abnormalities although these caused no significant prolongation of bleeding time.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: Abnormalities of thrombocyte number and function may increase the tendency to bleed in the setting of liver cirrhosis.
📊
Key Findings & Data:Methods: A total of 42 cases (23 male, 19 female; with a mean age of 44.8 years) comprising 17 cirrhosis, 15 chronic active hepatitis and 10 healthy control patients were studied.
💡
Conclusion & Impact:In the cirrhotic stage, however, there were significant functional abnormalities although these caused no significant prolongation of bleeding time.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Kan trombositleri · Kanama · Karaciğer sirozu

Abstract

Background/Aims: Abnormalities of thrombocyte number and function may increase the tendency to bleed in the setting of liver cirrhosis. The aim of this study was to determine the relationship between the stage of liver disease and thrombocyte functions. Methods: A total of 42 cases (23 male, 19 female; with a mean age of 44.8 years) comprising 17 cirrhosis, 15 chronic active hepatitis and 10 healthy control patients were studied. In all cases complete blood counts, bleeding time and prothrombin time and blood chemistries were determined as well as maximum aggregation rate, maximum aggregation severity and adenosine 3 phosphate secretion upon induction with three different agents (adenosine diphosphate, collagen and ristocetin). Results: There was no significant difference between the hepatitis and control group for any parameter. Mean maximum aggregation rate and mean maximum aggregation severity induced by Adenosine diphosphate, collagen and ristocetin and mean adenosine 3 phosphale secretion levels induced by collagen and ristocetin were significantly lower in the cirrhosis group (p<0.05). The decrease in thrombocyte aggregation rate, aggregation severity and adenosine 3 phosphale secretion were found to be independent of thrombocyte number. Conclusions: In the chronic active hepatitis stage of liver disease, functional abnormality of thrombocytes was not detected. In the cirrhotic stage, however, there were significant functional abnormalities although these caused no significant prolongation of bleeding time.

Özet

Amaç: Karaciğer sirozu olan olgularda trombositlerdeki sayısal ve fonksiyonel bozukluklar kanama eğilimini arttırabilir. Çalışmamızın amacı karaciğer hastalığının evresi ile trambosit fonksiyonları arasındaki ilişkiyi belirlemektir. Yöntem: On yedi siroz, 15 kronik aktif hepatit ve 10 normal birey olmak üzere toplam 42 vaka (23 erkek, 19 kadın; ortalama yaş 44.8) çalışmaya alındı. Tüm vakalarda tam kan sayımı, kanama zamanı, protrombin zamanı, kan biyokimyasına ilave olarak adenozin 2 fosfat, kollajen ve ristosetin uyarılmasıyla traombositlerin maksimal agregasyon hızı, maksimum agregasyon şiddeti ve adenozin 3 fosfat salınımı ölçüldü. Bulgular: Kronik aktif hepatit ve kontrol grupları arasında herhangi bir parametre açısından anlamlı fark yoktu. Adenozin 2 fosfat, kollajen ve ristosetinle uyarılan maksimal agregasyon hızı ve maksimum agregasyon şiddeti siroz grubunda diğer gruplara göre anlamlı olarak düşüktü (P<0.05). Trombosit agregasyon hızı, agregasyon şiddeti ve adenozin 3 fosfat sekresyonu ndaki düşmenin trombosit sayısından bağımsız olduğu belirlendi. Sonuç: Karaciğer hastalığının kronik aktif hepatit evresinde trombosit fonksiyon bozukluğu saptanmadı. Fakat siroz evresinde belirgin kanama zamanı uzamasına sebep olmayan fonksiyon bozukluğu saptandı.

🔖

Cite This Article

KAYA, M., YAMAN, A., BAKANAY, Ş. M., KURŞUN, N., KARAYALÇIN, S. (2001). Kronik karaciğer hastalığının evresi ile trombosit fonksiyonları arasındaki ilişki. Turkish Journal of Gastroenterology, Cilt: 12 - Sayı: 1, 13–18. https://ajindex.com/articles/410492

References (15)

  1. Kelly DA, Tuddenhan EGD. Haemostatic problems in liver disease. Gut 1986; 27: 339-49
  2. Laffi G, Cinotti S, Filimberti E, et al. Defective aggregation in cirrhosis is independent of invivo platelet activation. J Hepatol 1996; 24: 436-43
  3. Thomas DP, Ream VJ, Stuart RK. Platelet aggregation in patients with Laennec’s cirrhosis of liver. N Eng J Med 1967; 136: 316-9
  4. Ingeberg S, Jacobsen P, Fischer E, et al. Platelet aggregation and release of ATP in patients with hepatic cirrhosis. Scand J Gastroenterol 1985; 20: 285-8
  5. Desal K, Bagget C, Belmamy MF, et al. Inhibition of platelet aggregation by abnormal high density lipoprotein particles in plasma from patients with hepatic cirrhosis. Lancet 1989; 693-5
  6. Rubin MH, Weston MJ, Langley PG, et al. Platelet function in chronic liver disease relationship to disease severity. Dig Dis Sci 1979; 24: 197-202
  7. Younger HM, Hadoke PW, Dillon JF, et al. Platelet functions in cirrhosis and the role of humoral factors. Eur J Gastroenterol Hepatol 1997; 9: 989-92
  8. Watanabe M, Shiraishi K, Itakura M, et al. Relationship between platelet membrane lipid compositions and platelet aggregability in alcoholic liver disease. Alcohol Clin Exp Res 1998; 22: 975-1025
  9. Laffi G, Comminelli F, Ruggiero M, et al. Altered platelet function in cirrhosis of liver. Impairment of inositol lipid and arachidonic acid metabolism in rsponse to agonist. Hepatology 1986; 6: 1620-6
  10. Toghill PJ, Green S. Platelet dynamics in chronic liver disease using the 111- Indium oxine label. Gut 1983; 24: 49-52
  11. Papatheodoridis GV, Patch D, Vebster GJM, et al. Infection and haemostasis in decompensated cirrhosis: A prospective study using thrombelastography. Hepatology 1999; 29: 1999
  12. Gschwantler M, Vavric J, Gebauer Axel, et al. Course of platelet counts in cirrhotic patients after implantation of a transjugular intrahepatic portosystemic shunt. A prospective, controlled study. J Hepatol 1999; 30: 254-9
  13. Stein SF, Harker LA. Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis. J Lab Clin Med 1982; 99: 217-30
  14. Sezai S, Kamisaka K, Ikegami F, et al. Regulation of hepatic thrombopoietin production by portal haemodynamics in liver cirrhosis. Am J Gastroenterol 1998; 93: 80-2
  15. De Noronha R, Taylor BA, Wild G, et al. Inter-relationships between platelet count, platelet IgG, immune complexes and severity of liver disease. Clin Lab Haematol 1991; 13: 127-35